Previous 10 | Next 10 |
home / stock / aezs:cc / aezs:cc news
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all ite...
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...
– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerat e recruitment for DETECT trial A ctively seeking alternate development and commercializatio...
U . S . sales of Macrile n ® for adult use to be temporarily discontinued as of May 23, 2023 , while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen ...
Pharmanovia to acquire license to GHRYVELIN ™ from Aeter n a Zentaris’ existing licensee, Consilient Health , effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (N...
Aeterna Zentaris focuse d on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen ™ in the U . S . and Canad a Company c ontinu es to build growing body of data ac...
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...
Live video webcast on Thursday , January 19 th at 3 :00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical comp...
– Company ended the quarter with $ 53.8 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc....
– Company ended the quarter with $58.2 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq:...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS:CC Stock Symbol:
TSXC Market:
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Tra...
Company ended the quarter with $29.5 million in cash DETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024 All-stock merger of equals transaction with Ceapro Inc. exp...
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...